ライフサイエンスコーパス: cognitive symptom

1 tive symptoms) and decreased working memory (cognitive symptoms).

2 ttle is known about the neural basis of this cognitive symptom.

3 tremor and additional symptomatology such as cognitive symptoms.

4 , is characterized by positive, negative and cognitive symptoms.

5 e of the striatum's potential involvement in cognitive symptoms.

6 regional patterns associated with motor and cognitive symptoms.

7 tic autonomic dysfunction prior to motor and cognitive symptoms.

8 ation of patients according to diagnosis and cognitive symptoms.

9 ation and might thereby produce negative and cognitive symptoms.

10 rker of HD (CAG-repeat length) and motor and cognitive symptoms.

11 for Alzheimer's disease before the onset of cognitive symptoms.

12 holinesterase inhibition therapy targets the cognitive symptoms.

13 ted at least 1 NPI symptom from the onset of cognitive symptoms.

14 in the previous month and from the onset of cognitive symptoms.

15 al nervous system, and some patients develop cognitive symptoms.

16 d prevention and treatment of stress-related cognitive symptoms.

17 logy develops many years before the onset of cognitive symptoms.

18 on to dementia in non-demented patients with cognitive symptoms.

19 nism in the etiology of the disorder and its cognitive symptoms.

20 in, particularly affecting males, as well as cognitive symptoms.

21 derstood, particularly prior to the onset of cognitive symptoms.

22 n trajectories, would determine the eventual cognitive symptoms.

23 unction in neurodevelopmental disorders with cognitive symptoms.

24 psychotic symptoms, as well as negative and cognitive symptoms.

25 nto delayed neurodegeneration accompanied by cognitive symptoms.

26 logy in comparison to patients who report no cognitive symptoms.

27 acterized by self-limited focal seizures and cognitive symptoms.

28 y distinct inflammation-related physical and cognitive symptoms.

29 ecurrent thoughts of death, and physical and cognitive symptoms.

30 vels were not associated with psychiatric or cognitive symptoms.

31 fficient for the development of positive and cognitive symptoms.

32 er's disease (AD) prior to the appearance of cognitive symptoms.

33 , and symptom factors and moderate to severe cognitive symptoms.

34 d glia and is responsible for both motor and cognitive symptoms.

35 is characterized by positive, negative, and cognitive symptoms.

36 s in both groups were seen in depressive and cognitive symptoms.

37 ng, abdominal issues, fatigue, headache, and cognitive symptoms.

38 h comorbid PTSD and history of TBI reporting cognitive symptoms.

39 ess dopamine is not involved in negative and cognitive symptoms.

40 s behavioral deficits linked to negative and cognitive symptoms.

41 ensional measures of positive, negative, and cognitive symptoms.

42 topology and may be associated with distinct cognitive symptoms.

43 ehavioral constructs related to negative and cognitive symptoms.

44 ich relates to genetic factors and motor and cognitive symptoms.

45 de only partial amelioration of negative and cognitive symptoms.

46 treating tardive dyskinesia and negative and cognitive symptoms.

47 CI 1.69 to 3.78), early dysphagia and early cognitive symptoms.

48 cacy, but it is unknown if ketamine improves cognitive symptoms.

49 dard care in cancer survivors self-reporting cognitive symptoms.

50 vious 6 to 60 months and reported persistent cognitive symptoms.

51 d at reducing amyloid-have failed to reverse cognitive symptoms.

52 isabling, and intertwined with emotional and cognitive symptoms.

53 of the human brain, long before the onset of cognitive symptoms.

54 in people seeking medical advice because of cognitive symptoms.

55 ive function was only weakly associated with cognitive symptoms.

56 uit formation that cascade into more complex cognitive symptoms.

57 attention deficits that exacerbate its other cognitive symptoms.

58 22q11.2 deletion-associated psychiatric and cognitive symptoms.

59 disorder-60 years (27-91 years), eight with cognitive symptoms-69 years (62-89 years), eight with mi

60 oms (15.58%; 8.29%), myalgia (3.24%; 1.54%), cognitive symptoms (7.88%; 3.95%), and anxiety/depressio

61 owed a promising reduction in depressive and cognitive symptoms across all measures for NSI-189, with

62 ossible neurobiological underpinnings of the cognitive symptoms affecting COVID-19 survivors.

63 -dementia drugs or cognitive stimulants) for cognitive symptoms after conventional chemotherapy have

64 Cognitive symptoms after coronavirus disease 2019 (Covid

65 predicted presence of self-reported mood and cognitive symptoms after menopause.

66 nes, resulting in a combinatory of motor and cognitive symptoms and abnormal protein aggregation.

67 models, associations were also found between cognitive symptoms and at least moderate interference wi

68 In Huntington's disease (HD), cognitive symptoms and cellular dysfunction precede the

69 tive contributions of 13 neuropathologies to cognitive symptoms and dementia in RHI-exposed brain don

70 presentation, including behavior, mood, and cognitive symptoms and dementia.

71 ly rank the importance and bothersomeness of cognitive symptoms and discussed the relevance of each t

72 co-localization with NET was associated with cognitive symptoms and disease severity of bvFTD.

73 in the cortex to contribute to negative and cognitive symptoms and disinhibits projections to mesost

74 clinical and demographic features, including cognitive symptoms and fatigue.

75 a model of AD precedes the onset of AD-like cognitive symptoms and is driven, to a large extent, by

76 (AOR, 1.27 [95% CI, 1.21-1.33]) and between cognitive symptoms and lower odds of full-time employmen

77 ning, while CBT alone significantly improved cognitive symptoms and mental health functioning.

78 ease is associated with greater non-amnestic cognitive symptoms and neuropathological burden than lat

79 impacts (RHI) is associated with later-life cognitive symptoms and neuropathologies, including chron

80 ti-Alzheimer lead with beneficial effects on cognitive symptoms and on some underlying disease mechan

81 In healthy subjects without cognitive symptoms and patients with mild cognitive impa

82 duce a wide range of positive, negative, and cognitive symptoms and psychophysiologic deficits in hea

83 (ii) weighting of physical, behavioural and cognitive symptoms and signs; (iii) 'anterior' versus 'p

84 stic of several types of dementia, preceding cognitive symptoms and structural brain changes.

85 dults with cancer should include support for cognitive symptoms and symptom clusters.

86 y designed trials that focus on the cardinal cognitive symptoms and their associated biomarkers in th

87 ioral or mood symptoms or both, 80 (95%) had cognitive symptoms, and 71 (85%) had signs of dementia.

88 ioral or mood symptoms or both, 23 (85%) had cognitive symptoms, and 9 (33%) had signs of dementia.

89 he, abdominal symptoms, myalgia, other pain, cognitive symptoms, and anxiety/depression).

90 determined on the basis of medical history, cognitive symptoms, and exclusionary criteria.

91 sease, predicting the timing of clinical and cognitive symptoms, and for recruitment and treatment mo

92 al problems pair, or a pair representing all cognitive symptoms, and implicated more distributed netw

93 ifficult to differentiate due to overlapping cognitive symptoms, and measures of apraxia, in particul

94 BT significantly improved fatigue, distress, cognitive symptoms, and mental health functioning, while

95 rst, before neurodegenerative biomarkers and cognitive symptoms, and neurodegenerative biomarkers bec

96 diseases characterized by pain, fatigue, and cognitive symptoms, and that affected patients may benef

97 ow SVD lesions contribute to neurological or cognitive symptoms, and the association with risk factor

98 Objective cognitive functioning (tests), cognitive symptoms, anxiety, depression, and fatigue wer

99 -beta (Abeta) deposition occurs years before cognitive symptoms appear and is considered a cause of A

100 early in the pathogenesis, and less so when cognitive symptoms appear.

101 this survey study of US adults suggest that cognitive symptoms are common among individuals with pos

102 Cognitive symptoms are common, and yet many who seek hel

103 Neuropsychiatric, or non-cognitive symptoms are increasingly recognized as manife

104 Prolonged neuropsychiatric and cognitive symptoms are increasingly reported in patients

105 Cognitive symptoms are often reported by those with a hi

106 The cellular mechanisms underpinning these cognitive symptoms are poorly understood.

107 functional neurological disorders, in which cognitive symptoms are present, associated with distress

108 Cognitive symptoms are prevalent in PBC independent of l

109 The presence and severity of cognitive symptoms as self-rated by participants were ch

110 disruption of specific WM tracts to the core cognitive symptoms associated with FTD.

111 Results from experiments in models of the cognitive symptoms associated with schizophrenia showed

112 c insights into the etiology of higher-order cognitive symptoms associated with the disease.

113 Cognitive symptoms at 12 months were reported in 25% of

114 e participants who received chemotherapy had cognitive symptoms at 6 months (32%) versus those who di

115 lated the deviations with clinical motor and cognitive symptoms at an individual level and compared c

116 ant TBI x sex interactions were observed for cognitive symptoms (B = 0.76; 5% false discovery rate-co

117 T) in the diagnostic workup of patients with cognitive symptoms before widespread implementation in c

118 ntly associated with severity of fatigue and cognitive symptoms (both r2 = 0.3, P < .0001).

119 8242 may have a role in the treatment of the cognitive symptoms, but not the positive or negative sym

120 ate with disease stage in patients with mild cognitive symptoms, but this is not the case for CSF Abe

121 as it precedes other pathological events and cognitive symptoms by decades.

122 Alleviation of a range of cognitive and non-cognitive symptoms by drugs that modulate the cholinergi

123 ther the timing of onset nor the severity of cognitive symptoms can be accurately predicted.

124 anisms by which GBA1L444P contributes to the cognitive symptoms clinically observed in PD and DLB.

125 a cluster, which was labeled as an emotional/cognitive symptom cluster.

126 mains related to the positive, negative, and cognitive symptom clusters of schizophrenia were affecte

127 an Impact of Event Scale score >=1.75]), and cognitive symptoms (Cognitive Failure Questionnaire-14 s

128 ntervention, Insight, led to improvements in cognitive symptoms compared with standard care.

129 Cognitive symptoms, complex movement deficits, and incre

130 lack of effective treatment for negative and cognitive symptoms contribute to poor outcome.

131 Perceived cognitive symptoms correlated with objectively assessed

132 ions are driven by patients that report mild cognitive symptoms, despite similar levels of biopsy B-a

133 were standardized measures of pain, fatigue, cognitive symptoms, distress, and mental health function

134 physiological tasks relevant to the negative/cognitive symptom domains of schizophrenia that are thou

135 dition to liver changes, BDL animals develop cognitive symptoms early in the disease process (before

136 the early clinical stages as well as before cognitive symptoms emerge-during the long preclinical st

137 9 condition, 955 (56.7%) reported at least 1 cognitive symptom experienced daily, compared with 3552

138 One of the cognitive symptoms experienced by schizophrenia patients

139 e is characterized by motor, behavioural and cognitive symptoms for which at present there are no dis

140 The study included 1,767 participants with cognitive symptoms from 4 independent secondary care coh

141 ain injury (TBI) survivors exhibit motor and cognitive symptoms from the primary injury that can beco

142 d distinguish cancer patients who experience cognitive symptoms from those who do not.

143 lar areas implicated for motor (PSP, MSA) or cognitive symptoms (FTD, ALS, PSP) in the diseases.

144 ntly with premorbid educational achievement, cognitive symptoms, global function, and illness duratio

145 rlier stages of the disease; even before any cognitive symptoms have appeared.

146 Studies of cognitive symptoms have commonly focused on prefrontal c

147 erapeutic interventions to help manage these cognitive symptoms have had conflicting results and no s

148 aracterized by persistent pain, fatigue, and cognitive symptoms, have been reported by many Gulf War

149 Negative and cognitive symptoms impair functioning in patients with p

150 ssion levels correlate with gait, urinary or cognitive symptom improvement after shunt surgery.

151 m, and impaired interference management is a cognitive symptom in many disorders.

152 multisensory integration is an understudied cognitive symptom in schizophrenia.

153 d not exist before COVID-19: fatigue in 31%, cognitive symptoms in 21%, and new-onset dyspnea in 16%.

154 elation with the presence of psychiatric and cognitive symptoms in a large sample (n = 5160) of patie

155 agonist oveporexton improved NT1-associated cognitive symptoms in adults.

156 Tau accumulation is closely related to cognitive symptoms in Alzheimer's disease (AD).

157 cs, modelling, and experimental treatment of cognitive symptoms in Alzheimer's disease.

158 Synaptic dysfunction is linked to cognitive symptoms in Alzheimer's disease.

159 s provide new insights into the mechanism of cognitive symptoms in BDL animals, suggesting that OCA t

160 ical explanation for the shared seizures and cognitive symptoms in CECTS.

161 SHANK3 gene is sufficient to cause profound cognitive symptoms in children.

162 underlie the vulnerability and expression of cognitive symptoms in depression.SIGNIFICANCE STATEMENT

163 for possible therapeutic amelioration of the cognitive symptoms in DS.

164 ction, the relationship between spindles and cognitive symptoms in epileptic encephalopathies has not

165 peutic approaches have failed to improve the cognitive symptoms in fully developed, chronic epilepsy.

166 ssessing whether early AD is responsible for cognitive symptoms in geriatric patients: (a) a conventi

167 e tested the hypothesis that psychiatric and cognitive symptoms in HD are influenced by the same comm

168 asticity could underlie the motor as well as cognitive symptoms in HD.

169 and pathophysiological mechanisms underlying cognitive symptoms in health and disease.

170 ns for the treatment of interference-related cognitive symptoms in neuropsychiatric disorders, partic

171 The histological underpinning of cognitive symptoms in older people has been demonstrated

172 a potential therapeutic approach to treating cognitive symptoms in patients suffering from METH use d

173 sing therapeutic approach for both motor and cognitive symptoms in patients with neurodegenerative at

174 mulation (tDCS) could improve both motor and cognitive symptoms in patients with neurodegenerative at

175 in cognitive CSTC circuits may contribute to cognitive symptoms in patients with Parkinson's disease.

176 cement, and in the treatment of positive and cognitive symptoms in patients with schizophrenia.

177 this study, we determined the prevalence of cognitive symptoms in PBC, examined the relationship bet

178 The frequent occurrence of cognitive symptoms in post-COVID-19 condition has been d

179 dualized diagnostics and outcome measures of cognitive symptoms in preclinical AD.

180 n disorders and shows promise in alleviating cognitive symptoms in some AD patients.

181 Cognitive symptoms in stress-related psychiatric disorde

182 To assess cognitive symptoms in the developing brain, we administe

183 cognition battery assessing the frequency of cognitive symptoms in the past week and patient Health Q

184 shed light on the prophylactic treatment of cognitive symptoms in the SZ.

185 ate gyrus function, suggests a mechanism for cognitive symptoms in TLE, and supports a long-standing

186 peutic approaches for cancer therapy-induced cognitive symptoms include CNS stimulants (eg, methylphe

187 The common cognitive symptoms include deficits in complex attention

188 alleviate behaviors that model negative and cognitive symptoms, including deficits in social interac

189 characterized by a high incidence of complex cognitive symptoms, including learning disabilities, att

190 physiological mechanisms thought to underlie cognitive symptoms, including the role of dopamine, chol

191 Screening for and addressing cognitive symptoms is an important component of the publ

192 y manifestations of PASC are linked with the cognitive symptoms is not known.

193 Cognitive symptoms, like impaired cognitive control, are

194 ort, loss of energy, sleep problems) and one cognitive symptom (little interest in doing things).

195 rthritis self-efficacy for pain (P = 0.002), cognitive symptom management (P = 0.004), and communicat

196 s study is to elucidate how patient-reported cognitive symptoms manifest from variations in hormone l

197 s systematic review and meta-analysis, acute cognitive symptoms, medical history of anxiety and/or de

198 symptoms (nervousness, emotional, sadness), cognitive symptoms (mental fogginess, slowness), and sym

199 Recruitment was targeted to enrich in cognitive symptoms (mild dementia, mild cognitive impair

200 y and informant-completed scales that assess cognitive symptoms, mood disturbances, and neurobehavior

201 VID population with enduring respiratory and cognitive symptoms more than two years after infection.

202 sted healthy controls and patients with mild cognitive symptoms (N=331) in the BioFINDER study, using

203 Cognitive symptoms negatively impact people with narcole

204 s are common, and yet many who seek help for cognitive symptoms neither have, nor go on to develop, d

205 ects was primarily characterized by mood and cognitive symptoms, not the classical neurovegetative si

206 nitive behaviors and could contribute to the cognitive symptoms observed in schizophrenia.

207 more prevalent and, for ALS, behavioural and cognitive symptoms occur more frequently.

208 lopmental disorder in which the emergence of cognitive symptoms occurs during early adolescence.

209 ecular mechanisms of neuronal dysfunction in cognitive symptoms of 22q11DS are poorly understood.

210 ay be a pathogenic event contributing to the cognitive symptoms of 22q11DS.

211 are considered to be causally related to the cognitive symptoms of AD.

212 inhibitors are the primary treatment for the cognitive symptoms of Alzheimer disease (AD).

213 /M(4)-preferring mAChR agonist developed for cognitive symptoms of Alzheimer's disease (AD), had unex

214 of Abeta pathological progression, prior to cognitive symptoms of Alzheimer's disease (AD).

215 kinase (PAK) are suspected to play a role in cognitive symptoms of Alzheimer's disease (AD).

216 hylphenidate, are used as treatments for the cognitive symptoms of Alzheimer's disease and attention

217 psychosocial support, 3480 (68.5%) reported cognitive symptoms of any severity, ranging from 59.5% i

218 ween brain overgrowth and the behavioral and cognitive symptoms of ASD is poorly understood.

219 In patients presenting with cognitive symptoms of dementia, regional brain metabolis

220 luated the role of the cholinergic system in cognitive symptoms of depression and unexpectedly observ

221 Somatic and cognitive symptoms of depression were assessed using the

222 ch less about the cellular mechanisms of the cognitive symptoms of depression.

223 ortant cellular mechanism that underlies the cognitive symptoms of depression.

224 srupted mesocortical dopamine contributes to cognitive symptoms of Parkinson's disease (PD).

225 e on how to best treat the cognitive and non-cognitive symptoms of patients with Alzheimer's disease

226 s a promising candidate for the treatment of cognitive symptoms of patients with schizophrenia, in pa

227 of new biomarkers and targeted therapies for cognitive symptoms of PD.

228 t to the study of executive dysfunctions and cognitive symptoms of psychiatric disorders.

229 The cognitive symptoms of schizophrenia (SZ) present a signi

230 The cognitive symptoms of schizophrenia are largely resistan

231 The cognitive symptoms of schizophrenia presumably result fr

232 nd behavioral flexibility, components of the cognitive symptoms of schizophrenia, that are not rescue

233 ibution of early striatal dysfunction to the cognitive symptoms of schizophrenia.

234 this deficiency is pertinent to treating the cognitive symptoms of schizophrenia.

235 iduals that resemble positive, negative, and cognitive symptoms of schizophrenia.

236 but they lack efficacy for the negative and cognitive symptoms of schizophrenia.

237 e the potential to correct both positive and cognitive symptoms of schizophrenia.

238 le of addressing the positive, negative, and cognitive symptoms of schizophrenia.

239 n the endocannabinoid system account for the cognitive symptoms of schizophrenia.

240 What causes the positive, negative, and cognitive symptoms of schizophrenia?

241 The behavioral and cognitive symptoms of severe psychotic disorders overlap

242 gives rise to the debilitating emotional and cognitive symptoms of stress-related psychiatric disorde

243 eed to explore novel approaches to treat the cognitive symptoms of the disease and in part to the dev

244 positive symptoms but also the negative and cognitive symptoms of the disease.

245 te vulnerability to experience affective and cognitive symptoms of the disorder.

246 sequential processing that contribute to the cognitive symptoms of the disorder.SIGNIFICANCE STATEMEN

247 e movement sleep behaviour disorder preceded cognitive symptom onset in six cases by a median of 10 y

248 Shorter disease duration from cognitive symptom onset to death was observed in men (be

249 's disease mutation or APOE genotype, age at cognitive symptom onset, and sex to 12 untreated partici

250 Ds or related strategies could improve their cognitive symptoms or slow decline.

251 ely referred, nondemented patients with mild cognitive symptoms (original cohort, n = 118; validation

252 oms in daily activities (P = .008) and fewer cognitive symptoms (P = .01).

253 ly predicted PPCS based on parent ratings of cognitive symptoms (p=0.001).

254 Cognitive symptoms persisting beyond the acute phase of

255 Adjudicated risk status was estimated by cognitive symptoms plus presence of moderate-to-severe w

256 decline was estimated primarily by baseline cognitive symptoms plus SVD risk factors.

257 Concordantly, humans with lasting cognitive symptoms post-COVID exhibit elevated CCL11 lev

258 viding a potential mechanism for some of the cognitive symptoms produced by this mutation, our findin

259 ce patient, family, and clinicians when mild cognitive symptoms prompt a search for diagnosis and man

260 inor depression is characterized by mood and cognitive symptoms rather than neurovegetative symptoms;

261 ymptoms can be alleviated by antipsychotics, cognitive symptoms remain unresponsive and novel paradig

262 d-worsening (SAW), encompassing physical and cognitive symptoms, resulting from smouldering pathologi

263 ed to assess and probe for the more reliable cognitive symptoms such as anhedonia, guilt, suicidal th

264 es include physical, sensory, emotional, and cognitive symptoms such as disability, negative affect,

265 zheimer's disease (AD) often begins with non-cognitive symptoms such as olfactory deficits, which can

266 n schizophrenic patients correlate with core cognitive symptoms, such as thought disorder and distrac

267 uropathology in olfactory brain areas before cognitive symptoms, suggesting the potential for olfacto

268 endophenotype for SZ linked to positive and cognitive symptoms, supporting current preclinical model

269 COVID-19 (Long COVID) includes physical and cognitive symptoms that can last long after acute infect

270 but could also serve as a substrate for the cognitive symptoms that comprise the early-stage patholo

271 leading to distressing motor, sensory and/or cognitive symptoms that demonstrate positive clinical si

272 nterneurons to MIA, leading to affective and cognitive symptoms that have high relevance for schizoph

273 recession underlies some of the disorganized cognitive symptoms that occur in schizophrenia.

274 tients with cancer are at risk of developing cognitive symptoms that often become evident during or a

275 rther examine type/sources of loneliness and cognitive symptoms to develop effective interventions th

276 potential ADAD, clinicians should note that cognitive symptoms typical of sporadic Alzheimer's disea

277 The presence of any cognitive symptom was associated with lower likelihood o

278 The presence of cognitive symptoms was associated with diminished likeli

279 de range of cancer types; higher severity of cognitive symptoms was consistently associated with high

280 The prevalence of cognitive symptoms was determined in 198 patients with P

281 resenting negative, positive, affective, and cognitive symptoms was identified as the most stable and

282 , bladder symptoms, gynaecological symptoms, cognitive symptoms, weight problems, vitality, and depre

283 Cognitive symptoms were assessed using the Psychomotor V

284 More daily cognitive symptoms were associated with a greater likeli

285 Moreover, emotional and cognitive symptoms were associated with changes in thala

286 Across the entire sample, moderate to severe cognitive symptoms were associated with recurrence or pr

287 Vasomotor symptoms, pain, mood, and cognitive symptoms were characteristic of menopause.

288 Cognitive symptoms were frequent in our PBC population,

289 This cross-sectional study found that cognitive symptoms were frequently reported by patients

290 treatment for COVID-19, physical, mental, or cognitive symptoms were frequently reported.

291 d with the Beck Depression Inventory-II, and cognitive symptoms were measured with neuropsychological

292 In the DIAN-OBS cohort, non-cognitive symptoms were more common at more severe stage

293 Moderate to severe cognitive symptoms were reported by 1544 patients (30.4%

294 tients (26.2% [95% CI, 20.8% to 32.2%]), and cognitive symptoms were reported by 39 of 241 patients (

295 een shown to improve positive, negative, and cognitive symptoms when used as add-on therapy for the t

296 ipsychotics improved positive, negative, and cognitive symptoms, whereas the partial agonist D-cyclos

297 is associated with a variety of physical and cognitive symptoms which typically diminish during the f

298 d 118 patients aged 60 to 80 years with mild cognitive symptoms who underwent flutemetamol F 18 ([18F

299 t characteristics of LLD and overlap of some cognitive symptoms with other dementias.

300 Alzheimer's disease can exacerbate its other cognitive symptoms, yet relevant disruptions of key pref